Main Outcome Measures
Abbreviations and Acronyms:AMD (age-related macular degeneration), CME (cystoid macular edema), FAF (fundus autofluorescence), IQR (interquartile range), logMAR (logarithm of the minimum angle of resolution), MNV (macular neovascularization), NIR (near-infrared reflectance), PPS (pentosan polysulfate sodium), RPE (retinal pigment epithelium), VA (visual acuity)
- Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment.J Urol. 2015; 193: 1545-1553
- Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis.Drugs. 2006; 66: 821-835
- Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium.Ophthalmology. 2018; 125: 1793-1802
- Phenotypic spectrum of pentosan polysulfate sodium-associated maculopathy: a multicenter study.JAMA Ophthalmol. 2019; 137: 1275-1282
- Strength of association between pentosan polysulfate and a novel maculopathy.Ophthalmology. 2019; 126: 1464-1466
- Prevalence of maculopathy associated with long-term pentosan polysulfate therapy.Ophthalmology. 2020; 127: 835-836
- Heparanase deficiency is associated with disruption, detachment, and folding of the retinal pigment epithelium.Curr Eye Res. 2020; : 1-5
- Re: Pearce et al.: Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium (Ophthalmology. 2018;125:1793-1802.Ophthalmology. 2019; 126: e51
- Pentosan polysulfate maculopathy.Surv Ophthalmol. 2021; S0039-6257: 00123-00125
- Elmiron (pentosan polysulfate sodium) [package insert]. Janssen Pharmaceuticals, Inc., Titusville, NJ2020
- Epidemiology of interstitial cystitis.Urology. 1997; 49: 2-9
- Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome.Can Urol Assoc J. 2011; 5: 113-118
- About Adult BMI.(2020)https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.htmlDate accessed: March 29, 2021
- Epidemiology of interstitial cystitis.Ann Chir Gynaecol Fenn. 1975; 64: 75-77
- Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort.Br J Ophthalmol. 2020; 104: 1093-1097
- Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis.Can J Ophthalmol. 2020; 55: 116-125
- A novel multimethod image analysis to quantify pentosan polysulfate sodium retinal toxicity.Ophthalmology. 2020; 127: 429-431
- Pentosan polysulfate maculopathy versus age-related macular degeneration: comparative assessment with multimodal imaging.Can J Ophthalmol. 2021 Mar 12; ([Epub ahead of print])
- Large subfoveal vitelliform lesions in a case of pentosan polysulfate maculopathy.Ophthalmology. 2020; 127: 1641
- Disease course in patients with pentosan polysulfate sodium-associated maculopathy after drug cessation.JAMA Ophthalmol. 2020; 138: 894-900
- Progressive maculopathy after discontinuation of pentosan polysulfate sodium.Ophthalmic Surg Lasers Imaging Retina. 2019; 50: 656-659
Publication stageIn Press Journal Pre-Proof
Supplemental material is available at www.ophthalmologyretina.org.
Financial Support: Foundation Fighting Blindness Career Development Award CD-C-0918-0748-EEC (NJ).
Disclosure(s): All authors have completed and submitted the ICMJE disclosures form.
The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Macula Society Pentosan Polysulfate Maculopathy Study Group
Bascom Palmer Eye Institute, University of Miami: Audina M. Berrocal, MD; Casey Eye Institute, Oregon Health and Science University: Brandon J. Lujan, MD; Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic: Tyler E. Greenlee, DO, Rishi P. Singh, MD; Emory Eye Center: Andrew Hendrick, MD, Nieraj Jain, MD, Albert Liao, MD, MS, Benjamin I. Meyer, MD, Ghazala A. O’Keefe, MD, Rachel Shah, MD, Jiong Yan, MD; Flaum Eye Institute, University of Rochester: Mina M. Chung, MD; Kellogg Eye Institute, University of Michigan: David N. Zacks, MD, PhD; Mid Atlantic Retina, The Retina Service of Wills Eye Hospital: Allen Chiang, MD, James P. Dunn, MD, Mitchell S. Fineman, MD, David H. Fischer, MD, Sunir J. Garg, MD, Omesh P. Gupta, MD/MBA, Allen C. Ho, MD, Jason Hsu, MD, Thomas L. Jenkins, MD, Richard S. Kaiser, MD, Carl H. Park, MD, Samir N. Patel, MD, Arunan Sivalingam, MD, Marc J. Spirn, MD, James F. Vander, MD, Yoshihiro Yonekawa, MD; Northern California Retina Vitreous Associates and University of California San Francisco: Rahul N. Khurana, MD; Retina Consultants of Hawaii: Gregg T. Kokame, MD, Maria Won; Retina Consultants of Texas: David M. Brown, MD, Charles C. Wykoff, MD, PhD, Amy C. Schefler, MD, Hannah J. Yu, BS; Retina Group of Florida: Lawrence S. Halperin, MD; Retina Consultants San Diego: Nikolas J. S. London, MD; University of California Davis Eye Center: Ala Moshiri, MD, PhD, Susanna S. Park, MD, PhD; University of Iowa Department of Ophthalmology and Visual Sciences: James C. Folk, MD, Elliott H. Sohn, MD, Alexis K. Warren, MD; Roski Eye Institute, University of Southern California: Linda A. Lam, MD, MBA; West Coast Retina: H. Richard McDonald, MD, Caleb C. Ng, MD, Michelle Y. Peng, MD; VitreoRetinal Surgery, PA: Peter J. Belin, MD, Robert A. Mittra, MD; Vitreous Retina Macula Consultants of New York: K. Bailey Freund, MD; Wilmer Eye Institute, Johns Hopkins University: Kapil Mishra, MD, Mandeep S. Singh, MD, PhD.
Conception and design: Jain, Khurana, Zacks
Data collection: Jain, Liao, Garg, Patel, Wykoff, Yu, London, Khurana, Zacks
Analysis and interpretation: Jain, Liao, Zacks
Obtained funding: Jain
Overall responsibility: Jain, Liao, Garg, Wykoff, London, Khurana, Zacks
HUMAN SUBJECTS: Human subjects were included in this study. The human ethics committees at the Emory University approved the study. All research adhered to the tenets of the Declaration of Helsinki. Informed consent was waived. No animal subjects were used in this study.